Kura Oncology (#KURA) CEO Troy Edward Wilson purchased another 100,000 shares at $12.39, worth approximately $1.24M, marking his second 100,000-share purchase this month. 🔹 Key Highlights 👤 CEO purchased 100,000 shares worth approximately $1.24M. 📈 This marks his second 100,000-share purchase this month. 🧪 KOMZIFTI (ziftomenib) is advancing through the KOMET-017 Phase 3 trial for frontline AML. 🔬 Multiple 2026 clinical data updates are expected across combination programs. 🧬 Darlifarnib is advancing in solid tumors. 🧪 KO-7246 is progressing toward IND-enabling studies. 💰 KOMZIFTI generated $9.1M Q2 revenue, up 57% QoQ. 👥 Approximately 115 new patient starts, up 35% QoQ. 💡 Why It Matters The combination of continued CEO insider buying, growing KOMZIFTI revenue, and multiple clinical catalysts gives Kura several potential drivers as it expands its oncology pipeline. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified